Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
British Journal of Pharmacology2021Vol. 179(11), pp. 2476–2489
Citations Over TimeTop 10% of 2021 papers
Daniel Stehle, Min Xu, Tibor Schomber, Michael G. Hahn, Frank Schweda, Susanne Feil, Jan R. Kraehling, Frank Eitner, Andreas Patzak, Peter Sandner, Robert Feil, Agnès Bénardeau
Abstract
This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.
Related Papers
- → BAY 60–2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs(2017)18 cited
- → Soluble guanylyl cyclase during postnatal porcine pulmonary maturation(2004)24 cited
- → Renal Blood Flow, Glomerular Filtration Rate, Renal PAH Extraction Ratio, and the Role of the Renal Vasomotor Nerves in the Unanesthetized Rabbit(1963)42 cited
- → Renal Haemodynamic Responses to Adenosine in Acute Renal Failure(1995)9 cited
- → Inhibition of Vascular Smooth Muscle Growth by the Soluble Guanylyl Cyclase Activator BAY 60–2770(2013)